DOP033 Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes
Vande Casteele N.*1,2, Jairath V.3,4, Levesque B.1,2, Feagan B.3,4, Sandborn W.1,2
1University of California, San Diego, United States 2Robarts Clinical Trials, Inc., San Diego, United States 3University of Western Ontario, London, Canada 4Robarts Clinical Trials, Inc., London, Canada
Therapeutic drug monitoring is a useful tool to optimize infliximab (IFX) therapy in clinical practice. The relationship between IFX concentration and change from baseline in endoscopic disease activity during induction and maintenance therapy is unknown.
Data from the randomized controlled ACT-1 and -2 trials encompassing 484 patients with ulcerative colitis treated with IFX therapy were analyzed. A two-compartment population pharmacokinetic model was used to estimate IFX clearance (CL) at baseline. The Mayo endoscopic score (MES; range 0–3, with 3 representing most severe inflammation) was available at Week (W) 0, W8 and W30. A test for a linear trend between mean baseline IFX CL and MES (0–3) at W8 was performed. A concentration-effect curve was established by sorting all patients from low to high IFX concentration at specific time points with corresponding change in MES from W0 to W8 (ΔMES8) and from W0 to W30 (ΔMES30). Receiver operating curve (ROC) analysis was performed to identify IFX concentration cut-points with combined maximal sensitivity and specificity that corresponded to a MES of 0–1 or 0. Patients with missing data at W8 and/or W30 were considered treatment failures.
A linear relationship was observed between baseline IFX CL and MES at W8 (p<0.001). Concurrently, approximate median baseline IFX half-life was significantly shorter in patients with W8 MES ≥2 vs W8 MES <2 (12 vs 15 days, respectively, p<0.001). In patients with higher IFX exposure during induction and maintenance therapy, ΔMES8 and ΔMES30 was greater (Fig. 1A and 1B, respectively).
IFX cut-points of 26 ug/mL at W2, 11 ug/mL at W6 and 35 ug/mL at W8 correlated with W8 MES <2, and 5.0 ug/mL at W14 and 2.3 ug/mL at W30 correlated with W30 MES <2 (Table 1).
Ulcerative colitis patients with high baseline IFX CL may benefit from accelerated dosing during induction treatment to achieve drug exposure above the cut-points associated with short- and long-term mucosal healing.